Musculoskeletal disorders

Medimaps Announces Reimbursement by Center for Medicare and Medicaid Services (CMS) for Trabecular Bone Score for Osteoporosis Fracture Risk Assessment

Retrieved on: 
Thursday, July 29, 2021

This is the first new reimbursable CPT code for fracture risk assessment in osteoporosis in almost a decade.

Key Points: 
  • This is the first new reimbursable CPT code for fracture risk assessment in osteoporosis in almost a decade.
  • The reimbursement amount was released by CMS last week and will become effective and available January 1, 2022.
  • This is largely a result of the fact that 75% of high-risk patients are not being diagnosed timely4.
  • Bone microarchitecture assessed by TBS predicts osteoporotic fractures independent of bone density: the Manitoba study, Journal of Bone and Mineral Research.

Miami Periodontist Implements New Treatment for TMJ Disorders

Retrieved on: 
Wednesday, July 28, 2021

MIAMI, July 28, 2021 /PRNewswire-PRWeb/ -- Miami Periodontist and Dental Implant Specialist Dr. John Paul Gallardo has announced a new method of treating TMJ disorder using laser therapy.

Key Points: 
  • MIAMI, July 28, 2021 /PRNewswire-PRWeb/ -- Miami Periodontist and Dental Implant Specialist Dr. John Paul Gallardo has announced a new method of treating TMJ disorder using laser therapy.
  • TMJ disorders include non alignment or injury to the teeth or jaw which limit the movement of the jaw joint and muscles around it.
  • TMJ disorders can be caused by teeth grinding or clenching, excessive chewing, and stress.
  • "There are several ways that doctors treat TMJ disorders whether it's with physical therapy or even surgery.

Studies Show Sustained Acoustic Medicine Effectively Treats Shoulder Injuries

Retrieved on: 
Tuesday, July 27, 2021

TRUMBULL, Conn., Jul 27, 2021 /PRNewswire/ --Two recently published studies found that the long-duration, wearable sustained acoustic medicine device from ZetrOZ Systems relieves pain from shoulder and other injuries when conservative therapies fail, and can be a replacement for pain medications.

Key Points: 
  • TRUMBULL, Conn., Jul 27, 2021 /PRNewswire/ --Two recently published studies found that the long-duration, wearable sustained acoustic medicine device from ZetrOZ Systems relieves pain from shoulder and other injuries when conservative therapies fail, and can be a replacement for pain medications.
  • "Sustained acoustic medicine gives doctors an additional way to treat musculoskeletal injuries and to treat post-operative pain, and avoid potentially addictive pain medications."
  • Sustained acoustic medicine provides an attractive home-use treatment option for patients suffering from upper trapezius myofascial pain."
  • The authorsconcluded that sustained acoustic medicine showed promise as a "self-applied effective therapy, and as a possible replacement or adjuvant to pharmacotherapies for shoulder pain."

Jiffy Lube® and Muscular Dystrophy Association Celebrate 10th Annual Fundraising Campaign to Support the Neuromuscular Community

Retrieved on: 
Tuesday, July 27, 2021

During the month of August, Jiffy Lube customers will be invited to make a donation of$3or more to MDA at participating Jiffy Lube centers.

Key Points: 
  • During the month of August, Jiffy Lube customers will be invited to make a donation of$3or more to MDA at participating Jiffy Lube centers.
  • "I'm honored to support the Muscular Dystrophy Association and Jiffy Lube's efforts to fund breakthrough science and care and commend them for their decade-long dedication of driving to do more to support MDA's mission."
  • "I'm so happy to be part of the Jiffy Lube campaign, because it is raising awareness about muscular dystrophy that I live with," said Maddee Helaire, MDA Ambassador.
  • For decades, the Muscular Dystrophy Association (MDA) has been committed to transforming the lives of people living with muscular dystrophy, ALS, and related neuromuscular diseases.

Strongbridge Biopharma plc Announces Publication of Long-term Efficacy and Safety Results for KEVEYIS® (dichlorphenamide) for the Treatment of Primary Periodic Paralysis in Muscle & Nerve

Retrieved on: 
Tuesday, July 13, 2021

The results confirmed that long-term treatment with KEVEYIS is safe and effective for chronic use.

Key Points: 
  • The results confirmed that long-term treatment with KEVEYIS is safe and effective for chronic use.
  • Collectively, these results reinforce the utility of KEVEYIS as an effective option in treating PPP, a life-long rare, hereditary skeletal muscle disorder that leads to debilitating attacks of muscle weakness.
  • KEVEYIS (dichlorphenamide) is indicated for the treatment of primary hyperkalemic periodic paralysis, primary hypokalemic periodic paralysis, and related variants.
  • The companys rare neuromuscular franchise includes KEVEYIS (dichlorphenamide), the first and only FDA-approved treatment for hyperkalemic, hypokalemic, and related variants of primary periodic paralysis.

Chicago Marathon Physician Offers Tips to Avoid Common Running Injuries

Retrieved on: 
Thursday, July 1, 2021

Injuries are very common among runners.Recent research estimates that 82% of runners will become injured during their running careerand up to 90% will experience injury while training for a marathon.

Key Points: 
  • Injuries are very common among runners.Recent research estimates that 82% of runners will become injured during their running careerand up to 90% will experience injury while training for a marathon.
  • Some of the most common include a stress fracture, plantar fasciitis, hamstring tendinitis, ankle sprain, runners' knee, and Achilles' tendonitis.
  • Here are some safety tips from Dr. Joshua Blomgren , a 15-time Chicago Marathon team physician and sports medicine physician, Midwest Orthopaedics at Rush :
    Don't increase weekly mileage or intensity by more than 10 percent each week.
  • If you would like to talk with Dr. Joshua Blomgren about your running injury, please visit www.rushortho.com or call 877.MD.BONES.

Muscular Dystrophy Association Releases New PSA Campaign with Indianapolis Colts Running Back Nyheim Hines

Retrieved on: 
Tuesday, June 15, 2021

Hines is a running back for the Indianapolis Colts of the National Football League (NFL).

Key Points: 
  • Hines is a running back for the Indianapolis Colts of the National Football League (NFL).
  • He has long been a supporter of MDA through the NFL's My Cause My Cleats campaign.
  • "MDA is the leading organization in advancing the community's needs and advocating for improving care and finding cures for people living with muscular dystrophy.
  • For 70 years, the Muscular Dystrophy Association (MDA) has been committed to transforming the lives of people living with muscular dystrophy, ALS, and related neuromuscular diseases.

ITO CO., LTD. Has Received Clearance From the U.S. Food and Administration (FDA) for Electrotherapy for Dental Use “D function”

Retrieved on: 
Friday, May 21, 2021

View the full release here: https://www.businesswire.com/news/home/20210521005067/en/\nElectrical Muscle Stimulator for TMJ Pain Relief D function (Graphic: Business Wire)\nD function is an Electrical Muscle stimulator, to treat temporomandibular joint dysfunction and associated pain.

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20210521005067/en/\nElectrical Muscle Stimulator for TMJ Pain Relief D function (Graphic: Business Wire)\nD function is an Electrical Muscle stimulator, to treat temporomandibular joint dysfunction and associated pain.
  • It is equipped with multiple treatment modes to relieve muscle spasms and helps to maintain balance and control of the nerves and muscles around the head and neck.
  • Relaxation and relief of pain observed in the temporomandibular joint can be attained by applying the highly functional waveforms.
  • In its essence, electrophysical agents involves not just technical capabilities, but establishing an approach founded on evidence-based medicine (EBM).

Global Ankylosing Spondylitis (Bekhterev's Disease) Epidemiology Forecast to 2030 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, May 11, 2021

Axial SpA is further divided into two subgroups as Ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA).\nThe disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Prevalence of Ankylosing Spondylitis, Diagnosed Prevalence of Ankylosing Spondylitis, Gender-specific Diagnosed Prevalence of Ankylosing Spondylitis, Age-specific Diagnosed Prevalence of Ankylosing Spondylitis, and Gene-specific Diagnosed Prevalence of Ankylosing Spondylitis scenario in the United States from 2018 to 2030.\nThe total prevalent population of Ankylosing Spondylitis (AS) in the US is anticipated to rise from 2018 to 2030.

Key Points: 
  • Axial SpA is further divided into two subgroups as Ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA).\nThe disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Prevalence of Ankylosing Spondylitis, Diagnosed Prevalence of Ankylosing Spondylitis, Gender-specific Diagnosed Prevalence of Ankylosing Spondylitis, Age-specific Diagnosed Prevalence of Ankylosing Spondylitis, and Gene-specific Diagnosed Prevalence of Ankylosing Spondylitis scenario in the United States from 2018 to 2030.\nThe total prevalent population of Ankylosing Spondylitis (AS) in the US is anticipated to rise from 2018 to 2030.
  • The prevalent cases are expected to increase at a CAGR of 0.97% for the study period of 2018-2030.\nThe prevalent population of Ankylosing Spondylitis (AS) showed a male predominance.
  • Additionally, there are no specific lab tests to identify ankylosing spondylitis.
  • Moreover, the model supports data presented in the report and showcases disease trends over the 10-year forecast period using reputable sources.\n3 Disease Background and Overview: Ankylosing Spondylitis (AS)\n'

Muscular Dystrophy Association's National Ambassador Ethan LyBrand to be featured in Verizon's National Ad Campaign Airing on the Oscars

Retrieved on: 
Thursday, April 22, 2021

b'NEW YORK, April 22, 2021 /PRNewswire/ -- Muscular Dystrophy Association today celebrates National Ambassador Ethan LyBrand and his parents Jordan and Josh LyBrand for their feature in the new Verizon advertising campaign airing on the Oscars this Sunday.\nEthan\'s MDA story received national recognition throughout the pandemic with his Shorty Award winning online "Joke-A-Day for MDA" campaign.

Key Points: 
  • b'NEW YORK, April 22, 2021 /PRNewswire/ -- Muscular Dystrophy Association today celebrates National Ambassador Ethan LyBrand and his parents Jordan and Josh LyBrand for their feature in the new Verizon advertising campaign airing on the Oscars this Sunday.\nEthan\'s MDA story received national recognition throughout the pandemic with his Shorty Award winning online "Joke-A-Day for MDA" campaign.
  • The campaign began when in-person events pivoted to a virtual format due to the pandemic.
  • Ethan\'s ad can be viewed here .\nFor 70 years, the Muscular Dystrophy Association (MDA) has been committed to transforming the lives of people living with muscular dystrophy, ALS, and related neuromuscular diseases.
  • MDA supports the largest network of multidisciplinary clinics providing best-in-class care at more than 150 of the nation\'s top medical institutions.